From: Low Dose Medicine: theoretical background and scientific evidence
Year | Authors | Journal | Study Type | Title | Molecules and Tested Drugs |
---|---|---|---|---|---|
2009 | Gariboldi S. et al. [26] | Pulmonary Pharmacology & Therapeutics | In vivo basic research | Low dose oral administration of cytokines for treatment of allergic asthma | IL-12 IFN-γ |
2012 | D’amico L. et al. [27] | Journal of Cancer Therapy | Ex vivo basic research | Low Dose of IL-12 stimulates T Cell response in cultures of PBMCs derived from Non-Small Cell Lung Cancer Patients | IL-12 |
2013 | Cardani D. et al. [28] | Gastroenterology Research | In vivo basic research | Oral Administration of Interleukin-10 and Anti-IL-1 Antibody Ameliorates Experimental Intestinal Inflammation. | IL-10 Antibodies-anti IL-1 |
2014 | Radice E. et al. [29] | International Immunopharmacology | Ex vivo basic research | Low-doses of sequential-kinetic-activated interferon-gamma enhance the ex vivo cytotoxicity of peripheral blood natural killer cells from patients with early-stage colorectal cancer. A preliminary study | IFN-γ |
2014 | Roberti ML. et al. [30] | Journal of Biological Regulatory & Homeostatic Agents | Clinical trial | Immunomodulating treatment with low dose Interleukin-4, Interleukin-10 and Interleukin-11 in psoriasis vulgaris. | IL-4 IL-10 IL-11 |
2015 | Luchetti P. [31] | Minerva Medica Oftalmologica | Clinical trial | Increasing of visual function in patients with retinal atrophy treated with drugs of Low Dose Medicine. Monocentric retrospective observational study. | NT3 NT4 NGF Retina suis Injeel Solanum compositum Ubichinon compositum |
2015 | Barygina V. et al. [32] | Journal of Dermatological Science | In vitro basic research | Treatment with low-dose cytokines reduces oxidative-mediated injury in perilesional keratinocytes from vitiligo skin. | IL-4 IL-10 b-FGF β-endorphin |
2015 | Lotti T. et al. [33] | Journal of Biological Regulatory & Homeostatic Agents | Clinical trial | Vitiligo: successful combination treatment based on oral low dose cytokines and different topical treatments. | IL-4 IL-10 Antibodies-anti IL-1 b-FGF |
2015 | Radice E. et al. [34] | Translational Oncology | Ex vivo basic research | Enhancement of the Immunostimulatory Functions of Ex Vivo-Generated Dendritic Cells from Early-Stage Colon Cancer Patients by Consecutive Exposure to Low Doses of Sequential-Kinetic-Activated IL-4 and IL-12. | IL-4 IL-12 |
2015 | Lotti T. et al. [35] | Der Hautarzt | Clinical trial | Successful combination treatment for psoriasis with phototherapy and low-dose cytokines: A spontaneous, retrospective observational clinical study. | IL-4 IL-10 Antibodies-anti IL-1 |
2016 | Barygina V. et al. [36] | Journal of Dermatological Science | In vitro basic research | Low dose cytokines reduce oxidative stress in primary lesional fibroblasts obtained from psoriatic patients. | IL-4 IL-10 b-FGF β-endorphin |
2016 | Fiorito F. et al. [37] | Comparative Immunology, Microbiology and Infectious Diseases | Clinical trial (veterinary) | Clinical improvement in feline herpesvirus 1 infected cats by oral low dose of interleukin-12 plus interferon-gamma. | IL-12 IFN-γ |
2016 | Genazzani A. et al. [38] | Bollettino di Ginecologia Endocrinologica Frontiers in Gynecological Endocrinology | Observational pilot study | Pharmacological and Integrative Treatment of Stress-Induced Hypothalamic Amenorrhea | Beta-Estradiol |
2017 | Martin Martin LS. et al. [39] | Drug Design, Development and Therapy | Clinical trial | An open randomized active-controlled clinical trial with low-dose SKA cytokines versus DMARDs evaluating low disease activity maintenance in patients with rheumatoid arthritis. | Antibodies-anti IL-1 IL-10 IL-4 |
2017 | Castiglioni S. et al. [40] | International Journal of Molecular Sciences | In vitro basic research | Femtograms of Interferon- γ Suffice to Modulate the Behavior of Jurkat Cells: A New Light in Immunomodulation | IFN-γ |
2018 | Mancini F. et al. [41] | International Immunopharmacology | In vitro basic research | Low-dose SKA Progesterone and Interleukin-10 modulate the inflammatory pathway in endometriotic cell lines | Progesterone IL-10 |